Table 2 Treatment patterns among pediatric patients across select countries/regions
Author year | Cohort age a | Sample size | ACEI/ARBs (%) | Other therapies (%) |
|---|---|---|---|---|
Mainland China | ||||
Zhao 2021 [41] | 8.4 ± 3.2 | 79 | 2.5 | Steroid + immunosuppressant (72.2), steroid (25.3) |
Wu 2020 [27] | 13.7 ± 3.7 | 1243 | 70 | Immunosuppressant (64), steroid (45), steroid + immunosuppressant (19) |
WGNSSDTCRD [11] | 10 (NR) | 1417 | 49.5 | Oral prednisone (47.5), intravenous methylprednisolone (21.8), CTX (19.6%), tripterygium wilfordii (15.2), MMF (6.3), leflunomide (1.7%), tonsillectomy (0.3) |
Japan | ||||
Matsuzaki 2013 [54] | NR | 92 | 95.7 | Antiplatelet agents (82.6), tonsillectomy + steroid (38), intravenous steroid (33.2%), oral steroid (30.4) |
Yata 2008 [49] Children with DMP | 10.9 (2.5–19.6) b | 108 | 0.9 | Immunosuppressant (68.5), steroid (23.1), antiplatelet agents (6.5%), no treatment (0.9) |
Yata 2008 [49] Children with FMP | 10.9 (2.5–19.6) b | 173 | 50.9 | No treatment (13.2), steroid + immunosuppressant (4.6), steroid (3.5%), antiplatelet agents (1.2) |
South Korea | ||||
Suh 2020 [73] | 11.41 ± 3.9 | 1154 | 31.9 | Immunosuppressant (50.2) |